Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00992563 | WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination | PHASE2 | COMPLETED | 35 | — | — | Jun 1, 2010 | May 1, 2011 | Jul 18, 2014 | - | — |
| Arm | Type | Description |
|---|---|---|
| AL-39324 Concentration Level A | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level B | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level C | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level D | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level E | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| Lucentis | ACTIVE_COMPARATOR | Ranibizumab 10 mg/mL solution, single intravitreal injection |
| Name | Type | Description |
|---|---|---|
| AL-39324 ophthalmic suspension | DRUG | - |
| Ranibizumab 10 mg/mL | DRUG | - |
Inclusion Criteria: * Willing to give written informed consent, make the required study visits and follow instructions; * The study eye: * must have a primary diagnosis of choroidal neovascularization (CNV) secondary to AMD; * lesion must be no larger than 30 mm2; * must have edema measuring...